Kailera Therapeutics to Present at ObesityWeek 2026

Kailera Therapeutics (KLRA) will present clinical trial designs and real-world obesity research at ObesityWeek 2026, taking place November 14–17 in Washington, D.C.

Rhea-AI Summary

Kailera Therapeutics (KLRA) will present clinical trial designs and real-world obesity research at ObesityWeek 2026, taking place November 14–17 in Washington, D.C.

Presentations on November 15 cover the design of the Phase 3 KaiNETIC-1, -2 and -3 trials evaluating ribupatide injection. November 16 presentations address methods for studying obesity medications in real-world use and unmet clinical needs among adults with Class II and III obesity. Hengrui Pharma will also present Phase 3 HARBOR-1 findings for safiglipron, which Kailera is developing outside Greater China. All presentations will be available on Kailera’s Scientific Publications webpage after the congress.

News Explained

Kailera says Hengrui is advancing once-daily oral ribupatide to Phase 3 trials in China, while Kailera plans global Phase 3 obesity trials for the oral formulation in the first half of 2027; the global trials are planned, not reported as underway.

Key Terms

glp-1, gip, nda, subcutaneous injection

4 terms

glp-1 medical

"GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide)"

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

gip medical

"GIP (glucose-dependent insulinotropic polypeptide) receptor dual agonist peptide"

GIP commonly stands for Global Infrastructure Partners, a private investment firm that buys and manages large physical assets such as airports, power plants, toll roads and pipelines. Investors pay attention because when GIP acquires, invests in, or sells such assets it can alter cash flow, debt levels and long-term plans for those businesses—like a new landlord changing rents or making upgrades—affecting revenue, dividends and risk for shareholders and creditors.

nda regulatory

"Hengrui submitted an NDA to the National Medical Products Administration"

An NDA, or nondisclosure agreement, is a legal contract that keeps certain information private between parties. It’s like a promise not to share sensitive details, helping protect business ideas, strategies, or data from being leaked or used without permission. For investors, NDAs help ensure that confidential information remains secure, enabling trust and open communication during business discussions.

subcutaneous injection medical

"once-weekly subcutaneous injection and as a once-daily oral pill"

A subcutaneous injection is a method of delivering a medicine or vaccine by inserting a small needle just under the skin into the thin layer of fat beneath the outer skin. For investors, administration by subcutaneous injection matters because it influences patient convenience, dosing frequency, manufacturing complexity and distribution costs, all of which affect how widely a treatment is adopted and how it is priced—like choosing a product that customers can easily use at home versus one that needs a clinic visit.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Ribupatide injection Phase 3 KaiNETIC trial design presentations highlight its potential to address diverse needs across the obesity spectrum
• Real-world obesity management presentation highlights the clinical unmet needs of people living with obesity

WALTHAM, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that new clinical and real-world research will be presented at ObesityWeek 2026, taking place November 14-17 in Washington, D.C. The research includes the design of the Phase 3 KaiNETIC trials evaluating ribupatide injection, alongside analyses examining real-world obesity management and clinical needs among people living with obesity.

“People living with obesity have diverse and often highly individualized treatment needs, underscoring the importance of developing new therapeutic options,” said Scott Wasserman, M.D., Chief Medical Officer of Kailera Therapeutics. “The research we are presenting at ObesityWeek reflects both the rigor of our clinical development program and our focus on better understanding the real-world obesity landscape and how our differentiated GLP-1-based pipeline can address unmet patient needs.”

ObesityWeek 2026 Presentations

Title	Presenter	Date
Rationale and design of the KaiNETIC-1 and -2 trials of ribupatide in people living with obesity	Dr. Vanita Aroda	November 15
Rationale and design of the KaiNETIC-3 trial of ribupatide in people with obesity and no diabetes	Dr. Ildiko Lingvay	November 15
Natural history and real-world effectiveness of obesity management medications: REFLECT design/methods	Briain O Hartaigh, Kailera	November 16
Quantifying the Clinical Unmet Need in Adults with Class II and III Obesity in the United States	Molly Plotkin, Kailera	November 16

In addition, Hengrui Pharma will present findings from its Phase 3 HARBOR clinical program evaluating safiglipron (KAI-7535, HRS-7535), an investigational oral small-molecule GLP-1 receptor agonist. Safiglipron is being developed by Kailera Therapeutics outside Greater China.

Additional Presentations by Hengrui Pharma at ObesityWeek 2026

Title	Date
HRS-7535 for Weight Management in Chinese Adults with Overweight or Obesity: Phase 3 HARBOR-1 Study	November 15
HRS-7535 Effect on Glycaemic Status in Prediabetes: HARBOR-1 Subgroup Analysis	November 15

All presentations will be accessible on the Scientific Publications section of the Kailera website following the congress. Additional information can be found on the ObesityWeek website.

About Ribupatide
Ribupatide is a GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide) receptor dual agonist peptide being developed as a once-weekly subcutaneous injection and as a once-daily oral pill for the treatment of obesity and overweight.

Once-weekly ribupatide injection has been studied in more than 3,000 clinical trial participants who have been dosed with treatment out to 52 weeks, including in multiple late-stage clinical trials conducted by Hengrui in China. Hengrui submitted an NDA to the National Medical Products Administration (NMPA) in China for long-term weight management in adults. In May 2024, Hengrui granted Kailera exclusive global rights outside Greater China to develop, manufacture and commercialize its portfolio of innovative GLP-1 therapeutics, including ribupatide injection and ribupatide oral. Kailera is currently evaluating ribupatide injection for the treatment of obesity in the KaiNETIC global Phase 3 clinical program.

Based on compelling clinical data to date, Hengrui is advancing once-daily ribupatide oral to Phase 3 clinical trials in China, and Kailera plans to initiate global Phase 3 trials in obesity in the first half of 2027.

About Kailera Therapeutics

Kailera Therapeutics (Kailera) is a clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. With an obesity-first focus, Kailera is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate, ribupatide injection (also known as KAI-9531), that has the potential for the greatest weight loss. Ribupatide injection is in global Phase 3 trials as a once-weekly injectable GLP-1/GIP receptor dual agonist. Kailera is expanding the ribupatide franchise by developing a once-daily oral formulation with the goal of providing an oral option with the potential for compelling weight loss and highly differentiated tolerability. Additionally, Kailera is advancing the development of safiglipron (also known as KAI-7535), a once-daily oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera’s vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. Kailera is based in Waltham, MA. For more information, visit www.kailera.com and follow us on LinkedIn and X.

Special Note Regarding Kailera Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the profile of product candidates, the potential of Kailera’s portfolio, the timing, design and outcome of research and development activities, including with respect to the timing of initiation and completion of clinical trials and the design and goals of clinical trials, market opportunities for product candidates, the competitive landscape, and participation in upcoming events. Forward-looking statements can be identified by terms such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," “suggest,” "plan," “goal,” “vision,” "potential," "predict," "project," "should," "target," "will," "would," or similar expressions and the negatives of those terms. Kailera cannot assure you that the forward-looking statements in this press release will prove to be accurate. Information in this press release may also include statements relating to past performance, which should not be regarded as a reliable indicator of future performance. Forward-looking statements are based on current expectations and assumptions together with projections of the future which are inherently uncertain, and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, uncertainties inherent in clinical development, regulatory review, manufacturing, competition, market opportunities, reliance on third parties, estimates of capital requirements, needs for additional financing, and other important factors, including those discussed under the caption “Risk Factors” in Kailera’s filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release, and Kailera undertakes no obligation to update or revise any forward-looking statements. Kailera may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on these forward-looking statements.

Contact Information

Maura Gavaghan
Vice President, Investor Relations
maura.gavaghan@kailera.com

Anna Robinson
Vice President, Communications
anna.robinson@kailera.com